Xian Deng
Stock Analyst at UBS
(4.55)
# 1,006
Out of 5,000 analysts
88
Total ratings
64.2%
Success rate
16.8%
Average return
Main Sectors:
Stocks Rated by Xian Deng
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| SWX: BIOV BioVersys AG | Reiterated: Buy | CHF 48.00 → CHF 47.00 | CHF 25.40 | +85.04% | 3 | Sep 10, 2026 | |
| ARGX argenx SE | Upgraded: Buy | $960 → $1,400 | $962.22 | +45.50% | 35 | Aug 26, 2026 | |
| EPA: IPN Ipsen S.A. | Reiterated: Hold | €170.00 | €149.10 | +14.02% | 24 | Aug 3, 2026 | |
| AMS: LKFT Lakefront Biotherapeutics NV | Reiterated: Hold | €30.00 | €26.66 | +12.53% | 4 | Apr 1, 2026 | |
| SWX: LONN Lonza Group AG | Reiterated: Buy | CHF 720.00 → CHF 605.00 | CHF 570.00 | n/a | 12 | Feb 6, 2023 | |
| FRA: MDG1 Medigene AG | Reiterated: Buy | €8.00 | €0.02 | n/a | 6 | Aug 4, 2022 | |
| AMS: CRBN Corbion N.V. | Reiterated: Buy | €31.00 | €22.46 | n/a | 4 | Nov 1, 2019 |
BioVersys AG
Sep 10, 2026
Reiterated: Buy
Price Target: CHF 48.00 → CHF 47.00
Current: CHF 25.40
Upside: +85.04%
argenx SE
Aug 26, 2026
Upgraded: Buy
Price Target: $960 → $1,400
Current: $962.22
Upside: +45.50%
Ipsen S.A.
Aug 3, 2026
Reiterated: Hold
Price Target: €170.00
Current: €149.10
Upside: +14.02%
Lakefront Biotherapeutics NV
Apr 1, 2026
Reiterated: Hold
Price Target: €30.00
Current: €26.66
Upside: +12.53%
Lonza Group AG
Feb 6, 2023
Reiterated: Buy
Price Target: CHF 720.00 → CHF 605.00
Current: CHF 570.00
Upside: n/a
Medigene AG
Aug 4, 2022
Reiterated: Buy
Price Target: €8.00
Current: €0.02
Upside: n/a
Corbion N.V.
Nov 1, 2019
Reiterated: Buy
Price Target: €31.00
Current: €22.46
Upside: n/a